TY  - JOUR
AU  - Günter, Manina
AU  - Mueller, Karin Anne Lydia
AU  - Salazar, Mathew J
AU  - Gekeler, Sarah
AU  - Prang, Carolin
AU  - Harm, Tobias
AU  - Gawaz, Meinrad Paul
AU  - Autenrieth, Stella
TI  - Immune signature of patients with cardiovascular disease predicts increased risk for a severe course of COVID-19.
JO  - European journal of immunology
VL  - 54
IS  - 11
SN  - 0014-2980
CY  - Weinheim
PB  - Wiley-VCH
M1  - DKFZ-2024-01571
SP  - e2451145
PY  - 2024
N1  - #EA:D431#LA:D431# / 2024 Nov;54(11):e2451145
AB  - Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection can lead to life-threatening clinical manifestations. Patients with cardiovascular disease (CVD) are at higher risk for severe courses of COVID-19. So far, however, there are hardly any strategies for predicting the course of SARS-CoV-2 infection in CVD patients at hospital admission. Thus, we investigated whether this prediction is achievable by prospectively analysing the blood immunophenotype of 94 nonvaccinated participants, including uninfected and acutely SARS-CoV-2-infected CVD patients and healthy donors, using a 36-colour spectral flow cytometry panel. Unsupervised data analysis revealed little differences between healthy donors and CVD patients, whereas the distribution of the cell populations changed dramatically in SARS-CoV-2-infected CVD patients. The latter had more mature NK cells, activated monocyte subsets, central memory CD4+ T cells, and plasmablasts but fewer dendritic cells, CD16+ monocytes, innate lymphoid cells, and CD8+ T-cell subsets. Moreover, we identified an immune signature characterised by CD161+ T cells, intermediate effector CD8+ T cells, and natural killer T (NKT) cells that is predictive for CVD patients with a severe course of COVID-19. Thus, intensified immunophenotype analyses can help identify patients at risk of severe COVID-19 at hospital admission, improving clinical outcomes through specific treatment.
KW  - Cardiovascular disease (Other)
KW  - Immune signature (Other)
KW  - Immuno‐response (Other)
KW  - SARS‐CoV‐2 infection (Other)
KW  - Spectral flow cytometry (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39094122
DO  - DOI:10.1002/eji.202451145
UR  - https://inrepo02.dkfz.de/record/292063
ER  -